WHAT IS CLAIMED IS:

1 Use of (i) an LHRH agonist or antagonist in association with (ii) the selective estrogen receptor modulator acolbifene (EM-652·HCl, EM-1538) in the preparation of a medicament for treating or reducing the likelihood of acquiring estrogen-related diseases comprising inhibiting ovarian hormonal secretion in a patient.

2 Use of (i) an LHRH agonist or antagonist in association with (ii) a selective estrogen receptor modulator and with (iii) a sex steroid precursor or prodrug thereof, or salt of the foregoing compounds in the preparation of a medicament for treating or reducing the likelihood of acquiring estrogen-related diseases comprising inhibiting ovarian hormonal secretion in a patient.

3 The use of claim 2 wherein the selective estrogen receptor modulator is acolbifene (EM-652·HCl, EM-1538).

4 The use of claim 1 or 2 wherein said estrogen- related disease is endometriosis.

5 The use of claim 1 or 2 wherein said estrogen-related diseases are uterine fibroids or uterine leiomyomas.

6 The use of claim 1 or 2 wherein said estrogen-related diseases are endometrial cancer, uterine cancer, uterine leiomyosarcomas, ovarian cancer or breast cancer.

7 The use of claim 1 or 2 wherein said estrogen-related diseases are polycystic ovary syndrome, dysfunctional uterine bleeding, vaginal bleeding, menorrhagia, premenstrual syndrome, migraine headache, cervical intraepithelial neoplasia or adenomyosis.

8 The use of claim 2 wherein the sex steroid precursor is selected from the group consisting of dehydroepiandrosterone, dehydroepiandrosterone sulphate, 4-androstene-3,17-dione, androst-5-ene-3ß,17ß-diol, prodrug thereof, or salt of the foregoing compounds.

9 The use of claim 2 wherein the sex steroid precursor is dehydroepiandrosterone.

10 The use of claim 1 or 2 wherein said patient is a human.

11 A kit comprising a first container containing a therapeutically effective amount of the selective estrogen receptor modulator acolbifene (EM-652·HCl, EM-1538) and further comprising a second container containing a therapeutically effective amount of at least one LHRH agonist or LHRH antagonist, when used in the use of any one of claims 1, 4-7, 10 and 20-21.

12 A kit comprising a first container containing a pharmaceutical formulation comprising a therapeutically effective amount of a selective estrogen receptor modulator and a therapeutically effective amount of at least one sex steroid precursor or prodrug thereof or salt of the foregoing compounds, and further comprising a second container containing a therapeutically effective amount of at least one LHRH agonist or LHRH antagonist, when used in the use of any one of claims 2-10 and 22-23.

13 The kit of claim 12 wherein the selective estrogen receptor modulator is acolbifene (EM-652·HCl, EM-1538).

14 A kit comprising a first container containing a therapeutically effective amount of a selective estrogen receptor modulator, a second container containing a therapeutically effective amount of at least one sex steroid precursor or prodrug thereof or salt of the foregoing compounds, and further comprising a third container containing a therapeutically effective amount of at least one LHRH agonist or LHRH antagonist, when used in the use of any one of claims 2-10 and 22-23.

15 The kit of claim 14 wherein the selective estrogen receptor modulator is acolbifene (EM-652·HCl, EM-1538).

16 The kit of any one of claims 12-15 wherein the sex steroid precursor is selected from the group consisting of dehydroepiandrosterone, dehydroepiandrosterone sulphate, 4-androstene-3,17-dione, androst-5-ene- 3ß,17ß-diol, prodrug thereof, or salt of the foregoing compounds.

17 The kit of any one of claims 12-15 wherein the sex steroid precursor is dehydroepiandrosterone.

18 The kit of claim 12 wherein the pharmaceutical formulation is selected from the group consisting of pill, capsule, tablet, cream, gel, intravaginal suppository and intravaginal ovule.

19 The use of claim 2 or kit of claim 12 or 14 wherein said selective estrogen receptor modulator is acolbifene (EM-652·HCl, EM-1538) and where said sex steroid precursor is dehydroepiandrosterone.

20 Use of (i) an LHRH agonist or antagonist in association with (ii) the selective estrogen receptor modulator acolbifene (EM-652·HCl, EM-1538) in the preparation of a medicament for treating or reducing the likelihood of acquiring endometriosis in a woman.

21 Use of (i) an LHRH agonist or antagonist in association with (ii) the selective estrogen receptor modulator acolbifene (EM-652·HCl, EM-1538) in the preparation of a medicament for treating or reducing the likelihood of acquiring uterine fibroids or uterine leiomyomas in a woman.

22 Use of (i) an LHRH agonist or antagonist in association with (ii) the selective estrogen receptor modulator acolbifene (EM-652·HCl, EM-1538) and with (iii) the sex steroid precursor dehydroepiandrosterone in the preparation of a medicament for treating or reducing the likelihood of acquiring endometriosis in a woman.

23 Use of (i) an LHRH agonist or antagonist in association with (ii) the selective estrogen receptor modulator acolbifene (EM-652·HCl, EM-1538) and with (iii) the sex steroid precursor dehydroepiandrosterone in the preparation of a medicament for treating or reducing the likelihood of acquiring uterine fibroids or uterine leiomyomas in a woman.

24 The use of any one of claims 1, 2 and 20-23 wherein the selective estrogen receptor modulator has no estrogenic activity on breast, uterine or endometrial tissues.

WHAT IS CLAIMED IS:

1. Use of (i) an LHRH agonist selected from the group consisting of leuprolide acetate, goserelin acetate, nafarelin, buserelin acetate, histrelin acetate, triptorelin acetate or pamoate, and deslorelin acetate or LHRH antagonist selected from the group consisting of abarelix, teverelix, cetrorelix acetate, ganirelix acetate, iturelix, acyline, degarelix, ornirelix, azaline B, ozarelix, LXT-101, elagolix, TAK-013, TAK-385, and T-98475 in association with (ii) a selective estrogen receptor modulator selected from the group consisting of Raloxifene, Tamoxifen, Toremifene, Arzoxifene (LY 353381), LY 335563 (Desmethylarzoxifene), LY 335124, LY 326315, CHF-4227, Lasofoxifene (CP-336,156), LY-2066948, LY-2120310, Ospemifene, Sivifene (A-007), TAS-108, Bazedoxifene acetate (TSE-424), Pipendoxifene (ERA-923), Afimoxifene, (Z)-4-hydroxytamoxifen, Clomiphene, Enclomiphene, Fispemifene, Acolbifene (EM-652·HCl, EM-1538), EM-652, EM-800, Droloxifene, Idoxifene, GW-5638, Iproxifen (TAT-59), GW-7603, Centchroman, Levormeloxifene, PSK-3471, BL-3040, SRI-16158, SRI-16137, Rad-1901, SERM 3471, HMR 3339, HMR 3656, CC 8490, and (+)-3-(4-Hydroxyphenyl)-2-[4-(2-piperidin-1-ylethoxy)phenyl]-4-(trifluoromethyl)-2H-chromen-7-ol and with (iii) a sex steroid precursor selected from the group consisting of dehydroepiandrosterone, dehydroepiandrosterone sulfate, 4-androstene-3,17-dione, and androst-5-ene-3β,17β-diol or salt of the foregoing compounds in the preparation of a medicament for treating or reducing the likelihood of acquiring estrogen-related diseases selected from the group consisting of endometriosis, uterine fibroids, uterine leiomyomas, endometrial cancer, uterine cancer, uterine leiomyosarcomas, ovarian cancer, breast cancer, polycystic ovary syndrome, dysfunctional uterine bleeding, vaginal bleeding, menorrhagia, premenstrual syndrome, migraine headache, cervical

intraepithelial neoplasia and adenomyosis, comprising inhibiting ovarian hormonal secretion in a patient.

2. The use of claim 1 wherein the selective estrogen receptor modulator is acolbifene (EM-652·HCl, EM-1538).

3. The use of claim 1 wherein said estrogen-related disease is endometriosis.

4. The use of claim 1 wherein said estrogen-related diseases are uterine fibroids or uterine leiomyomas.

5. The use of claim 1 wherein said estrogen-related diseases are endometrial cancer, uterine cancer, uterine leiomyosarcomas, ovarian cancer or breast cancer.

6. The use of claim 1 wherein said estrogen-related diseases are polycystic ovary syndrome, dysfunctional uterine bleeding, vaginal bleeding, menorrhagia, premenstrual syndrome, migraine headache, cervical intraepithelial neoplasia or adenomyosis.

7. The use of claim 1 wherein the sex steroid precursor is selected from the group consisting of dehydroepiandrosterone, dehydroepiandrosterone sulfate, 4-androstene-3,17-dione, and androst-5-ene-3β,17β-diol.

8. The use of claim 1 wherein the sex steroid precursor is dehydroepiandrosterone.

9. The use of claim 1 wherein said patient is a human.

10. A kit comprising a first container containing a pharmaceutical formulation comprising a therapeutically effective amount of a selective estrogen receptor modulator selected from the group consisting of Raloxifene, Tamoxifen, Toremifene, Arzoxifene (LY 353381), LY 335563 (Desmethylarzoxifene), LY 335124, LY 326315, CHF-4227, Lasofoxifene (CP-336,156), LY-2066948, LY-2120310, Ospemifene, Sivifene (A-007), TAS-108, Bazedoxifene acetate (TSE-424), Pipendoxifene (ERA-923), Afimoxifene, (Z)-4-hydroxytamoxifen, Clomiphene, Enclomiphene, Fispemifene, Acolbifene (EM-652·HCl, EM-1538), EM-652, EM-800, Droloxifene, Idoxifene, GW-5638, Iproxifen (TAT-59), GW-7603, Centchroman, Levormeloxifene, PSK-3471, BL-3040, SRI-16158, SRI-16137, Rad-1901, SERM 3471, HMR 3339, HMR 3656, CC 8490, and (+)-3-(4-Hydroxyphenyl)-2-[4-(2-piperidin-1-ylethoxy)phenyl]-4-(trifluoromethyl)-2H-chromen-7-ol and a therapeutically effective amount of at least one sex steroid precursor selected from the group consisting of dehydroepiandrosterone, dehydroepiandrosterone sulfate, 4-androstene-3,17-dione, and androst-5-ene-3β,17β-diol or salt of the foregoing compounds, and further comprising a second container containing a therapeutically effective amount of at least one LHRH agonist selected from the group consisting of leuprolide acetate, goserelin acetate, nafarelin, buserelin acetate, histrelin acetate, triptorelin acetate or pamoate, and deslorelin acetate or LHRH antagonist selected from the group consisting of abarelix, teverelix, cetrorelix acetate, ganirelix acetate, iturelix, acyline, degarelix, ornirelix, azaline B, ozarelix, LXT-101, elagolix, TAK-013, TAK-385, and T-98475, when used in the use of any one of claims 1-9 and 18-19.

11. The kit of claim 10 wherein the selective estrogen receptor modulator is acolbifene (EM-652·HCl, EM-1538).

12. A kit comprising a first container containing a therapeutically effective amount of a selective estrogen receptor modulator selected from the group consisting of Raloxifene, Tamoxifen, Toremifene, Arzoxifene (LY 353381), LY 335563 (Desmethylarzoxifene), LY 335124, LY 326315, CHF-4227, Lasofoxifene (CP-336,156), LY-2066948, LY-2120310, Ospemifene, Sivifene (A-007), TAS-108, Bazedoxifene acetate (TSE-424), Pipendoxifene (ERA-923), Afimoxifene, (Z)-4-hydroxytamoxifen, Clomiphene, Enclomiphene, Fispemifene, Acolbifene (EM-652·HCl, EM-1538), EM-652, EM-800, Droloxifene, Idoxifene, GW-5638, Iproxifen (TAT-59), GW-7603, Centchroman, Levormeloxifene, PSK-3471, BL-3040, SRI-16158, SRI-16137, Rad-1901, SERM 3471, HMR 3339, HMR 3656, CC 8490, and (+)-3-(4-Hydroxyphenyl)-2-[4-(2-piperidin-1-ylethoxy)phenyl]-4-(trifluoromethyl)-2H-chromen-7-ol, a second container containing a therapeutically effective amount of at least one sex steroid precursor selected from the group consisting of dehydroepiandrosterone, dehydroepiandrosterone sulfate, 4-androstene-3,17-dione, and androst-5-ene-3β,17β-diol or salt of the foregoing compounds, and further comprising a third container containing a therapeutically effective amount of at least one LHRH agonist selected from the group consisting of leuprolide acetate, goserelin acetate, nafarelin, buserelin acetate, histrelin acetate, triptorelin acetate or pamoate, and deslorelin acetate or LHRH antagonist selected from the group consisting of abarelix, teverelix, cetrorelix acetate, ganirelix acetate, iturelix, acyline, degarelix, ornirelix, azaline B, ozarelix, LXT-101, elagolix, TAK-013, TAK-385, and T-98475, when used in the use of any one of claims 1-9 and 18-19.

13. The kit of claim 12 wherein the selective estrogen receptor modulator is acolbifene (EM-652·HCl, EM-1538).

14. The kit of any one of claims 10-13 wherein the sex steroid precursor is selected from the group consisting of dehydroepiandrosterone, dehydroepiandrosterone sulfate, 4-androstene-3,17-dione, and androst-5-ene-3β,17β-diol.

15. The kit of any one of claims 10-13 wherein the sex steroid precursor is dehydroepiandrosterone.

16. The kit of claim 10 wherein the pharmaceutical formulation is selected from the group consisting of pill, capsule, tablet, cream, gel, intravaginal suppository and intravaginal ovule.

17. The use of claim 1 or kit of claim 10 or 12 wherein said selective estrogen receptor modulator is acolbifene (EM-652·HCl, EM-1538) and where said sex steroid precursor is dehydroepiandrosterone.

18. Use of (i) an LHRH agonist selected from the group consisting of leuprolide acetate, goserelin acetate, nafarelin, buserelin acetate, histrelin acetate, triptorelin acetate or pamoate, and deslorelin acetate or LHRH antagonist selected from the group consisting of abarelix, teverelix, cetrorelix acetate, ganirelix acetate, iturelix, acyline, degarelix, ornirelix, azaline B, ozarelix, LXT-101, elagolix, TAK-013, TAK-385, and T-98475 in association with (ii) the selective estrogen receptor modulator acolbifene (EM-652·HCl, EM-1538) and with (iii) the sex steroid precursor dehydroepiandrosterone in the preparation of a medicament for treating or reducing the likelihood of

acquiring endometriosis in a woman.

19. Use of (i) an LHRH agonist selected from the group consisting of leuprolide acetate, goserelin acetate, nafarelin, buserelin acetate, histrelin acetate, triptorelin acetate or pamoate, and deslorelin acetate or LHRH antagonist selected from the group consisting of abarelix, teverelix, cetrorelix acetate, ganirelix acetate, iturelix, acyline, degarelix, ornirelix, azaline B, ozarelix, LXT-101, elagolix, TAK-013, TAK-385, and T-98475 in association with (ii) the selective estrogen receptor modulator acolbifene (EM-652·HCl, EM-1538) and with (iii) the sex steroid precursor dehydroepiandrosterone in the preparation of a medicament for treating or reducing the likelihood of acquiring uterine fibroids or uterine leiomyomas in a woman.